Immunogenic Targets for Specific Immunotherapy in Multiple Myeloma
Multiple myeloma remains an incurable disease although the prognosis has been improved by novel therapeutics and agents recently. Relapse occurs in the majority of patients and becomes fatal finally. Immunotherapy might be a powerful intervention to maintain a long-lasting control of minimal residua...
Main Authors: | Lu Zhang, Marlies Götz, Susanne Hofmann, Jochen Greiner |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Clinical and Developmental Immunology |
Online Access: | http://dx.doi.org/10.1155/2012/820394 |
Similar Items
-
Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
by: Alfonso Serrano-del Valle, et al.
Published: (2019-04-01) -
Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
by: Ken Maes, et al.
Published: (2019-07-01) -
Response: Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
by: Alfonso Serrano Del Valle, et al.
Published: (2019-11-01) -
BCMA-targeted immunotherapy for multiple myeloma
by: Bo Yu, et al.
Published: (2020-09-01) -
Immunotherapy for Multiple Myeloma
by: Nicolaus Kröger, et al.
Published: (2012-01-01)